American Journal of Kidney Diseases
Volume 52, Issue 1 , Pages 74-84 , July 2008

Kidney Function and Risk Factors for Left Ventricular Hypertrophy in Untreated Uncomplicated Essential Hypertension

  • Francesco Perticone, MD

      Affiliations

    • Department of Experimental and Clinical Medicine, G. Salvatore, University Magna Græcia of Catanzaro, Reggio Calabria, Italy
    • ,
  • Raffaele Maio, MD

      Affiliations

    • Department of Experimental and Clinical Medicine, G. Salvatore, University Magna Græcia of Catanzaro, Reggio Calabria, Italy
    • ,
  • Carmen Ruberto, MD

      Affiliations

    • Department of Experimental and Clinical Medicine, G. Salvatore, University Magna Græcia of Catanzaro, Reggio Calabria, Italy
    • ,
  • Susanna Cassano, MD

      Affiliations

    • Department of Experimental and Clinical Medicine, G. Salvatore, University Magna Græcia of Catanzaro, Reggio Calabria, Italy
    • ,
  • Giovanni Tripepi, StatDr

      Affiliations

    • Consiglio Nazionale delle Ricerche, Istituto di Biomedicina, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    • ,
  • Maria Perticone, MD

      Affiliations

    • Department of Experimental and Clinical Medicine, G. Salvatore, University Magna Græcia of Catanzaro, Reggio Calabria, Italy
    • ,
  • Giorgio Sesti, MD

      Affiliations

    • Department of Experimental and Clinical Medicine, G. Salvatore, University Magna Græcia of Catanzaro, Reggio Calabria, Italy
    • ,
  • Carmine Zoccali, MD

      Affiliations

    • Consiglio Nazionale delle Ricerche, Istituto di Biomedicina, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    • Corresponding Author InformationAddress correspondence to Carmine Zoccali, MD, CNR-IBIM, Istituto di Biomedicina, Epidemiologia Clinica e Fisiopatologia, delle Malattie Renali e dell'Ipertensione Arteriosa, 89100 Reggio Calabria, Italy.

Received 12 October 2007 ,Accepted 26 February 2008.

References 

  1. Devereux RB, Okin PM, Roman MJ. Left ventricular hypertrophy as a surrogate end-point in hypertension. Clin Exp Hypertens. 1999;21:583–593
  2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–1566
  3. Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 Years of follow-up. J Hypertens Suppl. 1996;14:S43–S49
  4. Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients. Ital Heart J. 2004;5:505–510
  5. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105–1187
  6. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med. 2001;161:886–891
  7. Fesler P, Du Cailar G, Ribstein J, Mimran A. Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol. 2003;14:881–887
  8. Schmieder RE, Messerli FH, Garavaglia G, Nunez B. Glomerular hyperfiltration indicates early target organ damage in essential hypertension. JAMA. 1990;264:2775–2780
  9. Perticone F, Maio R, Ceravolo R, Cosco C, Cloro C, Mattioli PL. Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Circulation. 1999;99:1991–1996
  10. Lind L, Andersson PE, Andren B, Hanni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens. 1995;13:433–438
  11. Pedrinelli R, Dell'Omo G, Di Bello V, et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol. 2004;24:2414–2419
  12. Viazzi F, Parodi D, Leoncini G, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005;45:991–996
  13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
  14. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes. 1998;47:1643–1649
  15. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056–1062
  16. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22–27
  17. Altman DG. Practical Statistics for Medical Research. In: London, UK: Chapman & Hall; 1998;p. 349–351
  18. Levin A, Ethier J, Carlisle EJ, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–134
  19. Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001;12:2768–2774
  20. Astor BC, Arnett DK, Brown A, Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2004;43:836–845
  21. Henry RM, Kamp O, Kostense PJ, et al. Mild renal insufficiency is associated with increased left ventricular mass in men, but not in women: An arterial stiffness-related phenomenon—The Hoorn Study. Kidney Int. 2005;68:673–679
  22. Smilde TD, Asselbergs FW, Hillege HL, et al. Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. Am J Hypertens. 2005;18:342–347
  23. Palmieri V, Okin PM, de Simone G, et al. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. J Hypertens. 2007;25:1079–1085
  24. Devereux RB. Hypertensive cardiac hypertrophy: Pathophysiologic and clinical characteristics. In:  Laragh JHBB editors. Hypertension: Pathophysiology, Diagnosis and Management. (ed 2). New York, NY: Raven; 1995;p. 409–424
  25. Vasan RS, Larson MG, Levy D, Evans JC, Benjamin EJ. Distribution and categorization of echocardiographic measurements in relation to reference limits: The Framingham Heart Study: Formulation of a height- and sex-specific classification and its prospective validation. Circulation. 1997;96:1863–1873
  26. Schmieder RE, Messerli FH, Ruddel H, et al. Sodium intake modulates left ventricular hypertrophy in essential hypertension. J Hypertens Suppl. 1988;6:S148–S150
  27. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: Relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001;38:1711–1717
  28. Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation. 2004;110:1456–1462
  29. Perticone F, Ceravolo F, Cosco C, et al. Deletion polymorphism of angiotensin-converting enzyme gene and left ventricular hypertrophy in southern Italian patients. J Am Coll Cardiol. 1997;29:365–369
  30. Pitt B, Zannad F, Phillips RA, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-Left Ventricular Hypertrophy Study. Circulation. 2003;108:1831–1838
  31. Verdecchia P, Reboldi G, Schillaci G, et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 1999;100:1802–1807
  32. Ceravolo R, Maio R, Cuda G, et al. Relation of fasting insulin related to insertion/deletion polymorphism of angiotensin-converting enzyme-gene and cardiac mass in never-treated patients with systemic hypertension. Am J Cardiol. 2003;92:1234–1237
  33. Sesti G, Sciacqua A, Scozzafava A, et al. Effects of growth hormone and insulin-like growth factor-1 on cardiac hypertrophy of hypertensive patients. J Hypertens. 2007;25:471–477
  34. Gonzalez A, Lopez B, Martin-Raymondi D, et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens. 2005;23:2297–2304
  35. Sciacqua A, Scozzafava A, Pujia A, et al. Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension. Eur Heart J. 2005;26:921–927
  36. Sciacqua A, Borrello F, Vatrano M, Grembiale RD, Perticone F. Effect of interaction between left ventricular dysfunction and endothelial function in hypertension. Curr Hypertens Rep. 2006;8:212–218
  37. Arnett DK, de las FL, Broeckel U. Genes for left ventricular hypertrophy. Curr Hypertens Rep. 2004;6:36–41
  38. Perticone F, Maio R, Di Paola R, et al. Role of PC-1 and ACE genes on insulin resistance and cardiac mass in never-treated hypertensive patients (Suggestive evidence for a digenic additive modulation). Nutr Metab Cardiovasc Dis. 2007;17:181–186
  39. Dell'Omo G, Penno G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis. 2002;40:1–8
  40. Watanabe S, Okura T, Liu J, et al. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 2003;26:895–899
  41. Leoncini G, Viazzi F, Parodi D, et al. Mild renal dysfunction and cardiovascular risk in hypertensive patients. J Am Soc Nephrol. 2004;15(suppl 1):S88–S90
  42. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective. Kidney Int. 2006;70:26–33
  43. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53:1343–1347
  44. Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50:723–728
  45. Perticone F, Maio R, Tripepi G, Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation. 2004;110:821–825
  46. Zoccali C, Maio R, Tripepi G, Mallamaci F, Perticone F. Inflammation as a mediator of the link between mild to moderate renal insufficiency and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006;17(suppl 2):S64–S68

 Originally published online as doi:10.1053/j.ajkd.2008.02.302 on April 21, 2008.

PII: S0272-6386(08)00532-5

doi: 10.1053/j.ajkd.2008.02.302

American Journal of Kidney Diseases
Volume 52, Issue 1 , Pages 74-84 , July 2008

Article Tools

* Image Usage & Resolution